Dyslipidemia: evidence of efficacy of the pharmacological and non-pharmacological treatment in the elderly
- Author:
- No author available
- Journal Title:
- JOURNAL OF GERIATRIC CARDIOLOGY
- Issue:
- 2
- DOI:
- 10.3724/SP.J.1263.2011.12292
- Key Word:
- Elderly patient;Risk factors;Dyslipidemia;Cardiovascular disease;Diet
Abstract： The clinical decision to control risk factors for cardiovascular disease (CVD) in the elderly takes the followings into consideration: (1) the elderly life expectancy; (2) the elderly biological age and functional capacity; (3) the role of cardiovascular disease in the elderly group; (4) the prevalence of risk factors in the elderly; and (5) The effectiveness of treatment of risk factors in the elderly. A large number of studies showed the efficacy of secondary and primary prevention of dyslipidemia in the elderly. However, the only trial that included patients over 80 years was the Heart Protection Study (HPS). Statins are considered the first line therapy for lowering low-density lipoprotein cholesterol (LDL-C). Because lifestyle changes are very difficult to achieve, doctors in general tend to prescribe many drugs to control cardiovascular risk factors. However, healthy food consumption remains a cornerstone in primary and secondary cardiovascular prevention and should be implemented by everyone.
- [1]Hong Shao,Li-Quan Chen,Jun Xu.Treatment of dyslipidemia in the elderly[J].2011,(1).
- [2]Leaf Alexander.Prevention of sudden cardiac death by n-3 polyunsaturated fatty acids[J].2007.
- [3]Breslow J L.n-3 Fatty acids and cardiovascular disease.[J].2006,83(6 S).
- [4]Carl J, Lavie.Assessment and treatment of lipids in elderly persons.[J].1900,13(3 Suppl 1).
- [5]Erik S. Stroes,Jaap Twisk,Melchior C. Nierman,etc.Intramuscular Administration of AAVl-Lipoprotein LipaseS447X Lowers Triglycerides in Lipoprotein Lipase-Deficient Patients[J].2008,28(12).
- [6]Steinberg D.An interpretive history of the cholesterol controversy: part I[J].2004,45(9).
- [7]Rozenn N, Lemaitre,Bruce M, Psaty,Susan R, Heckbert,etc.Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study.[J].2002,162(12).
- [8]Belder R,McCabe CH,Hill KA,etc.Intensive versus moderate lipid lowering with statins after acute coronary syndromes.[J].2004,350(15).
- [9]Murphy MB,Bollen EL,Perry IJ,etc.Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.[J].2002,360(9346).
- [10]Scott M, Grundy,James I, Cleeman,C Noel Bairey, Merz,etc.Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.[J].2004,110(2).
- [11]Godfrey S, Getz,Catherine A, Reardon.Nutrition and cardiovascular disease.[J].2007,27.
- [12]Baigent C,Blackwell L,Emberson J,etc.Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.[J].2010,376(9753).
- [13]Moll FL,van Oostrom O,de Vries JP,etc.Age-related changes in plaque composition A study in patients suffering from carotid artery stenosis.[J].2005,14(3).
- [14]Barter P,Mitchel Y,Ashraf TB,etc.Safety of anacetrapib in patients with or at high risk for coronary heart disease.[J].2010,363(25).
- [15]Steinberg D.Thematic review series: the pathogenesis of atherosclerosis: an interpretive history of the cholesterol controversy, part III: mechanistically defining the role of hyperlipidemia.[J].2005,46(10).
- [16]Steinberg D.Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans.[J].2005,46(2).
- [17]Roth EM,Rhyne J,Stein EA.Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.[J].2010,31(4).
- [18].MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.[J].2002,360(9326).
- [19]Aditi Sapre,Gary L. Carlson,Daniel Bloomfield.Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients[J].2009,157(2).
- [20]Rubins, Hanna Bloomfield,Robins, Sander J.,Collins, Dorothea,etc.Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol.[J].1999,341(6).
- [21]Halcox J,Wood D,Filardi PP,etc.ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).[J].2011,217(1).
- [22]LaRosa JC,Grundy SM,Shear C,etc.Intensive lipid lowering with atorvastatin in patients with stable coronary disease.[J].2005,352(14).
- [23]Koenig W,Libby P,Willerson JT,etc.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.[J].2008,359(21).
- [24]Tardif JC,Kastelein JJ,Waters DD,etc.Effects of torcetrapib in patients at high risk for coronary events.[J].2007,357(21).